<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05000372</url>
  </required_header>
  <id_info>
    <org_study_id>2021KT86</org_study_id>
    <nct_id>NCT05000372</nct_id>
  </id_info>
  <brief_title>68Ga-grazytracer PET/CT in Subjects With Non-small Cell Lung Cancer or Melanoma</brief_title>
  <official_title>68Ga-grazytracer PET/CT of Tumor Responses to Immunotherapy in Subjects With Non-small Cell Lung Cancer or Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Peking University Health Science Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Beijing Cancer Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label positron emission tomography/computed tomography (PET/CT) study to&#xD;
      investigate the clinical predictive value of 68Ga-grazytracer in subjects with non-small cell&#xD;
      lung cancer or melanoma receiving immune checkpoint inhibitors (e.g., Ipilimumab, Nivolumab).&#xD;
      A single dose of 2.96 MBq/kg body weight of 68Ga-grazytracer will be injected intravenously.&#xD;
      The visual and semiquantitative methods will be used to assess the PET/CT images.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators recently developed a granzyme B-specific radiotracer named&#xD;
      68Ga-grazytracer. This clinical trial aims to investigate whether granzyme B PET imaging&#xD;
      using 68Ga-grazytracer could early identify tumor responses to immune checkpoint inhibitory&#xD;
      cancer therapy in subjects with non-small cell lung cancer or melanoma. PET/CT imaging of&#xD;
      68Ga-grazytracer will be performed in subjects before and after receiving immune checkpoint&#xD;
      inhibitors.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 15, 2021</start_date>
  <completion_date type="Anticipated">August 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2023</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Single Group Assignment</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual assessment of lesions</measure>
    <time_frame>1 year</time_frame>
    <description>Visual analysis of 68Ga-grazytracer PET images will be performed by consensus reading by at least 3 experienced nuclear medicine physician.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Semiquantitative assessment of lesions</measure>
    <time_frame>1 year</time_frame>
    <description>The standardized uptake values (SUVs) of 68Ga-grazytracer in lesions will be measured by the same nuclear medicine physician for all the cases</description>
  </primary_outcome>
  <other_outcome>
    <measure>Granzyme B expression analysis of tumor tissues</measure>
    <time_frame>1 year</time_frame>
    <description>Tumor tissues obtained from biopsy or surgery will be stained for granzyme B</description>
  </other_outcome>
  <other_outcome>
    <measure>Correlation analysis of 68Ga-grazytracer uptake and lesion size changes</measure>
    <time_frame>1 year</time_frame>
    <description>The SUVs of 68Ga-grazytracer in individual lesions will be compared to the changes in lesion sizes</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>68Ga-grazytracer PET/CT in participants before immunotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who have not undergone immunotherapy will be injected with 2.96 MBq/kg body weight of 68Ga-grazytracer in one dose intravenously and then undergo PET/CT scan within 1 h.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>68Ga-grazytracer PET/CT in participants after immunotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants post-immunotherapy will be injected with 2.96 MBq/kg body weight of 68Ga-grazytracer in one dose intravenously and then undergo PET/CT scan within 1 h.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>68Ga-grazytracer</intervention_name>
    <description>68Ga-grazytracer PET/CT: after intravenous injection of 2.96 MBq/kg body weight of quality-controlled 68Ga-grazytracer, a Siemens Biograph PET/CT scan will be applied within 1 h, and the scan range will be from the top of the head to 1/3 of the upper thigh.</description>
    <arm_group_label>68Ga-grazytracer PET/CT in participants after immunotherapy</arm_group_label>
    <arm_group_label>68Ga-grazytracer PET/CT in participants before immunotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 18-75 years old;&#xD;
&#xD;
          2. ECOG score 0 or 1 point;&#xD;
&#xD;
          3. Participants with suspected or confirmed non-small cell lung cancer or melanoma who&#xD;
             are suggested by the clinicians to conduct PET/CT imaging for tumor diagnosis or&#xD;
             staging.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant or nursing;&#xD;
&#xD;
          2. Severe hepatic or renal dysfunction;&#xD;
&#xD;
          3. Low WBC (less than 3 x 10^9/L);&#xD;
&#xD;
          4. Unable to comply with the PET/CT imaging procedures.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nan Li, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Beijing Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Haoyi Zhou</last_name>
    <phone>+8610-82802893</phone>
    <email>2011110024@bjmu.edu.cn</email>
  </overall_contact>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 27, 2021</study_first_submitted>
  <study_first_submitted_qc>August 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 11, 2021</study_first_posted>
  <last_update_submitted>August 3, 2021</last_update_submitted>
  <last_update_submitted_qc>August 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Cancer Hospital</investigator_affiliation>
    <investigator_full_name>Hua Zhu</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <keyword>PET/CT</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Immune checkpoint inhibition</keyword>
  <keyword>Granzyme B</keyword>
  <keyword>68Ga labeling</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

